In addition to the anti-diabetic effect of metformin, a growing number of studies have shown
that metformin has some exciting properties, such as anti-oxidative capabilities, anticancer …

Heart failure is one of the leading causes of death and disability worldwide. Left ventricle
remodeling, fibrosis, and ischemia/reperfusion injury all contribute to the deterioration of …

AMP-activated protein kinase (AMPK) has been shown to inhibit cardiac hypertrophy. Here,
we show that submaximal AMPK activation blocks cardiomyocyte hypertrophy without …

Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting
from defects in insulin secretion and/or action. One of the most important complications of …

Perivascular adipose tissue (PVAT) is an active endocrine and paracrine organ that
modulates vascular function, with implications for the pathophysiology of cardiovascular …

Recent studies suggest that cardiac fibroblast-specific p38α MAPK contributes to the
development of cardiac hypertrophy, but the underlying mechanism is unknown. Our study …

Doxorubicin (DOX) is an antineoplastic agent obtained from Streptomyces peucetius. It is
utilized in treating different kinds of cancers, such as leukemia, lymphoma, and lung, and …

Simvastatin (SIM) is a lipid-soluble inhibitor of hydroxy-3-methylglutaryl coenzyme A
reductase with multiple reported therapeutic benefits. The present study was designed to …

Increasing evidence suggests that the widely used antidiabetic drug metformin have an
extensive therapeutic range beyond hypoglycemic therapy. We previously found that …

Introduction Heart failure is a complex clinical syndrome resulting from the unsuccessful
compensation of symptoms of myocardial damage. Mitochondrial dysfunction is a process …